Effect of patient thickness on acute gastrointestinal toxicities following radiotherapy for prostate cancer
Abstract
BACKGROUND: There is conflicting literature regarding the effect of patient size on radiotherapy toxicities. This study aimed to determine whether there is any association between patient thickness and severity and incidence of acute GI toxicities of prostate cancer patients receiving VMAT radiotherapy. The impact of confounding factors was also examined: rectal dose, age and lymph node irradiation.
MATERIALS AND METHODS: This study used a non-experimental, retrospective, descriptive and cross-sectional design. All patients who complied with the inclusion criteria (n = 96) were included. GI toxicity scores (baseline and last week of radiotherapy), rectal dose, lymph nodes irradiation and patient age at diagnosis were collected from the treatment file. Patient separations were measured from the CT-Simulator images. Statistical tests were performed to analyse the influence of these factors on acute GI toxicities.
RESULTS: Patient thickness was shown to have no statistically significant effect on the incidence (p = 0.947 for antero-posterior and p = 0.839 for lateral thicknesses), and severity (p = 0.986 and 0.905, respectively) of acute GI toxicities. Severity of GI toxicities increased following radiotherapy: the Expanded Prostate Cancer Index Composite (EPIC) score increased by 2.64 from baseline (p < 0.001). The confounding factors had no statistically significant effect on toxicities (p > 0.05).
CONCLUSION: As expected, most patients experienced an increase in GI toxicity following radiotherapy. No relationship was established between patient thickness and the severity or incidence of acute GI toxicities, adding to the existing body of knowledge. Therefore, all patients should receive adequate follow up, irrespective of size. Side-effect recording tools should be implemented systematically for continuous assessment of this relationship.
Keywords: separationthicknesspatient sizegastrointestinal toxicityprostate cancer
References
- Cherry P, Duxbury AM. Practical radiotherapy physics and equipment. 3rd ed. John Wiley & Sons, London 2019.
- Beyzadeoglu M, Ozyigit G, Ebruli C. Radiobiology. In: Basic radiation oncology. 2010th ed. Springer, New York 2010.
- Peach MS, Showalter TN, Ohri N. Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer. Prostate Cancer. 2015; 2015: 624736.
- World Health Organisation. Cancer country profiles. WHO, Geneva 2014.
- Flores-Cisneros L, Castro-Eguiluz D, Reyes-Barretero DY, et al. Effects of Dietary Components During and After Concomitant Chemoradiotherapy, Radiotherapy, or Sequential Chemoradiotherapy to the Abdominopelvic Area. Rev Invest Clin. 2018; 70(3): 126–129.
- Barrett A, Dobbs J, Morris S, Roques T. Practical radiotherapy planning. 4th ed. Hodder Arnold, London 2009.
- Doi H, Ishimaru F, Tanooka M, et al. Body mass index can affect gastrointestinal and genitourinary toxicity in patients with prostate cancer treated with external beam radiation therapy. Oncol Lett. 2014; 7(1): 209–214.
- Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004; 22(4): 648–657.
- Smits A, McGrane J, Lopes A, et al. Radiation-related toxicities and outcomes in endometrial cancer: are obese women at a disadvantage? Int J Clin Oncol. 2017; 22(5): 945–953.
- Doi H, Ishimaru F, Tanooka M, et al. Is obesity correlated with gastrointestinal toxicity induced by radiotherapy for prostate cancer? Radiother Oncol. 2012; 103: S427.
- von Gruenigen VE, Tian C, Frasure H, et al. Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma : a Gynecologic Oncology Group study. Cancer. 2006; 107(12): 2786–2791.
- Kizer NT, Thaker PH, Gao F, et al. The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer. 2011; 117(5): 948–956.
- Dandapani SV, Zhang Y, Jennelle R, et al. Radiation-Associated Toxicities in Obese Women with Endometrial Cancer: More Than Just BMI? ScientificWorldJournal. 2015; 2015: 483208.
- Smyth H. Does Obesity Impact Treatment Outcome for Prostate Cancer Patients Treated with Radiotherapy: The Weighted Debate. J Cancer Prev Curr Res. 2014; 2(1).
- Showalter TN, Lawrence YR, Xu X, et al. The Influence of Obesity on Toxicity and Biochemical Control after External Beam Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2009; 75(3): S351–S352.
- Wu WC, Chang YR, Lai YL, et al. Impact of body-mass factors on setup displacement during pelvic irradiation in patients with lower abdominal cancer. Radiol Oncol. 2019; 53(2): 256–264.
- von Hafe P, Pina F, Pérez A, et al. Visceral fat accumulation as a risk factor for prostate cancer. Obes Res. 2004; 12(12): 1930–1935.
- Koneru H, Cyr R, Feng LiR, et al. The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer. Cureus. 2016; 8(7): e669.
- Gar-Alnabi MEM, Mohamed EA, Ali Om, et al. Estimation of dose received by sensitive organs in external radiation therapy of cervical carcinoma. Int J Sci Res. 2014; 3(6): 1694–1698.
- Mitsuyama H, Wallner E, Merrick S. Gregory. Treatment of prostate cancer in obese patients. Oncology. 2006; 20(10): 1191–1197.
- Brown A, Tan A, Cooper S, et al. Obesity does not influence prostate intrafractional motion. J Med Radiat Sci. 2018; 65(1): 31–38.
- Bishop MJ, Miller SR, Joiner MC, et al. Obesity and Hypofractionated Prostate Radiotherapy: Evaluation of Body Mass Index Influence on Dose-Volume Plan Characteristics. Int J Radiat Oncol Biol Phys. 2017; 99(2): E638–E639.
- Sabater S, Arenas M, Berenguer R, et al. Body Mass Index and Doses at Organs at Risk in a Mediterranean Population Treated with Postoperative Vaginal Cuff Brachytherapy. Cancer Res Treat. 2015; 47(3): 473–479.
- Tiberi D, Gruszczynski N, Meissner A, et al. Influence of body mass index and periprostatic fat on rectal dosimetry in permanent seed prostate brachytherapy. Radiat Oncol. 2014; 9(1): 93.
- Cesaretti J, Stone N, Stock R. Does prior transurethral resection of prostate compromise brachytherapy quality: A dosimetric analysis. Int J Radiat Oncol Biol Phys. 2004; 60(2): 648–653.
- Michigan Medicine — Urology. Expanded prostate cancer index composite. Updated 2019. https://medicine.umich.edu/dept/urology/research/epic. (11/04, 2019).
- Wei J, Dunn R, Litwin M, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000; 56(6): 899–905.
- Owens A, Flinton D. Quantitative methods and analysis. In: Ramlau A. ed. Medical imaging and radiotherapy research skills and strategies. 1st ed. Churchill Livingstone, London : 183.
- Beyzadeoglu M, Ozyigit G, Ebruli C. Genitourinary system cancers. In: Basic radiation oncology 2010th ed. Springer, New york 2010.
- Deng X, Han Ce, Chen S, et al. Dosimetric benefits of intensity-modulated radiotherapy and volumetric-modulated arc therapy in the treatment of postoperative cervical cancer patients. J Appl Clin Med Phys. 2017; 18(1): 25–31.
- Teoh M, Clark CH, Wood K, et al. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011; 84(1007): 967–996.
- Barnett GC, West CML, Dunning AM, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer. 2009; 9(2): 134–142.
- Ferreira MR, Thomas K, Truelove L, et al. Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer. Clin Oncol (R Coll Radiol). 2019; 31(6): 374–384.
- Hamstra DA, Stenmark MH, Ritter T, et al. Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013; 85(5): 1246–1253.